Housed within the Siteman Cancer Center, the Biologic Therapy Core Facility (BTCF) partners with physicians and scientists to manufacture, characterize, and release complex, clinical-grade cell and gene therapy products, imaging agents, and other biologics to support early-phase clinical trials.
The BTCF also supports cellular (e.g. hematopoietic stem cell selections) and tissue therapies (e.g. parathyroid cryopreservation) for Barnes-Jewish Hospital patient care. In addition, the BTCF serves as a source of institutional expertise in current Good Manufacturing Practices (cGMP) to investigators across the institution to ensure strict adherence to phase-appropriate cGMP procedures & regulations in order to provide the highest level of drug or biologic, or cellular product quality for clinical trials…
Read the full article here.
